JP6238977B2 - 視神経症または先天性視神経萎縮を治療するためのアンギオテンシン変換酵素阻害薬 - Google Patents

視神経症または先天性視神経萎縮を治療するためのアンギオテンシン変換酵素阻害薬 Download PDF

Info

Publication number
JP6238977B2
JP6238977B2 JP2015519375A JP2015519375A JP6238977B2 JP 6238977 B2 JP6238977 B2 JP 6238977B2 JP 2015519375 A JP2015519375 A JP 2015519375A JP 2015519375 A JP2015519375 A JP 2015519375A JP 6238977 B2 JP6238977 B2 JP 6238977B2
Authority
JP
Japan
Prior art keywords
ophthalmic
optic
administered
optic neuropathy
ace
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015519375A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015522000A (ja
JP2015522000A5 (enExample
Inventor
ラオフ・レキク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2015522000A publication Critical patent/JP2015522000A/ja
Publication of JP2015522000A5 publication Critical patent/JP2015522000A5/ja
Application granted granted Critical
Publication of JP6238977B2 publication Critical patent/JP6238977B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2015519375A 2012-06-29 2013-06-28 視神経症または先天性視神経萎縮を治療するためのアンギオテンシン変換酵素阻害薬 Expired - Fee Related JP6238977B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TN20120343 2012-06-29
TNTN2012/0343 2012-06-29
PCT/IB2013/001375 WO2014001889A1 (en) 2012-06-29 2013-06-28 Angiotensin converting enzyme inhibitors for treating optic neuropathy or congenital optic atrophy

Publications (3)

Publication Number Publication Date
JP2015522000A JP2015522000A (ja) 2015-08-03
JP2015522000A5 JP2015522000A5 (enExample) 2016-08-12
JP6238977B2 true JP6238977B2 (ja) 2017-11-29

Family

ID=52471712

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015519375A Expired - Fee Related JP6238977B2 (ja) 2012-06-29 2013-06-28 視神経症または先天性視神経萎縮を治療するためのアンギオテンシン変換酵素阻害薬

Country Status (7)

Country Link
US (1) US9730949B2 (enExample)
EP (1) EP2866805A1 (enExample)
JP (1) JP6238977B2 (enExample)
CA (1) CA2877590A1 (enExample)
RU (1) RU2658461C2 (enExample)
WO (1) WO2014001889A1 (enExample)
ZA (1) ZA201500103B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108452309B (zh) * 2018-03-05 2019-08-23 佳木斯大学附属第一医院 一种用于预防或治疗视神经炎的药物组合物及其制备方法
RU2704013C1 (ru) * 2019-04-18 2019-10-23 ФГБНУ "НИИ глазных болезней" Способ коррекции окислительного стресса при наследственной оптической нейропатии Лебера

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656188A (en) * 1985-10-09 1987-04-07 Merck & Co., Inc. Ace inhibitors in macular degeneration
MXPA01012907A (es) * 1999-06-16 2003-06-24 Rekik Elyes Ben Mohamed Raouf Medicamentos oftalmologicos neutro - protectores y retino - protectores.
FR2826276A1 (fr) * 2001-06-20 2002-12-27 Raouf Rekik Administration des inhibiteurs de l'enzyme de conversion de l'angiotensine dans les degradations visuelles des sujets ages dues a la presbytie
RU2281023C2 (ru) * 2004-10-26 2006-08-10 Наталия Ивановна Курышева Способ прогнозирования течения глаукоматозной оптической нейропатии
EP3332766A1 (en) 2009-04-28 2018-06-13 BioElectron Technology Corporation Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur

Also Published As

Publication number Publication date
JP2015522000A (ja) 2015-08-03
RU2658461C2 (ru) 2018-06-21
US20150174146A1 (en) 2015-06-25
WO2014001889A1 (en) 2014-01-03
US9730949B2 (en) 2017-08-15
CA2877590A1 (en) 2014-01-03
EP2866805A1 (en) 2015-05-06
RU2014152906A (ru) 2016-08-20
ZA201500103B (en) 2016-05-25

Similar Documents

Publication Publication Date Title
Alipour et al. Use of mini scleral contact lenses in moderate to severe dry eye
JP6208235B2 (ja) 多発性硬化症治療のためのビオチンの使用
Pilz et al. A review of mitochondrial optic neuropathies: from inherited to acquired forms
JP2020045354A (ja) 薬学的組成物、および１，２，４−オキサジアゾール安息香酸の塩
Safarzadeh et al. Comparison of the clinical efficacy of preserved and preservative-free hydroxypropyl methylcellulose-dextran-containing eyedrops
Sahin et al. Effect of oral citicoline therapy on retinal nerve fiber layer and ganglion cell-inner plexiform layer in patients with primary open angle glaucoma
JP2024133735A (ja) Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物
Sacchi et al. Medical management of pediatric glaucoma: lessons learned from randomized clinical trials
Babizhayev Current ocular drug delivery challenges for N-acetylcarnosine: novel patented routes and modes of delivery, design for enhancement of therapeutic activity and drug delivery relationships
Gedik et al. Sildenafil-associated consecutive nonarteritic anterior ischaemic optic neuropathy, cilioretinal artery occlusion, and central retinal vein occlusion in a haemodialysis patient
JP6238977B2 (ja) 視神経症または先天性視神経萎縮を治療するためのアンギオテンシン変換酵素阻害薬
Khalaj et al. Relationship between diabetes and intraocular pressure
JP2022547401A (ja) 翼状片に関連した眼の見た目についての心配を軽減するための方法
Shiragami et al. Effect of topical isopropyl unoprostone on macular atrophy progression in eyes with exudative age-related macular degeneration
ES2324200T3 (es) Medicamentos oftalmologicos retino-protectores, que comprenden ramipril o ramiprilato.
RU2489146C1 (ru) Способ лечения "сухой" формы возрастной макулярной дегенерации
Miyashiro et al. Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
Gkoumas et al. Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Following a Hypovolemic Episode of Gastric Bleeding
Lee et al. Clinical features of idiopathic juxtafoveal telangiectasis in Koreans
Whitcup et al. A phase IIa multicenter, randomized, vehicle-controlled, dose escalating study to evaluate the safety, efficacy, and pharmacokinetics of CBT-001 ophthalmic solution in patients with primary or recurrent pterygium
Quiroga et al. Waking up blind in the ICU: a case report of ischemic optic neuropathy in a burn patient
Ausó et al. Visual Side Effects Linked to Sildenafil Consumption: An Update. Biomedicines 2021, 9, 291
Wijitsettakul et al. The efficacy and safety of on-demand elonza; a generic product of sildenafil in Thai men with erectile dysfunction
JPH11292764A (ja) グルタミン酸類が関与する疾患の治療および／または予防薬
Zhalalova et al. MODERN METHODS OF THERAPY OF VARIOUS FORMS OF OPTIC NERVE ATROPHY

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170807

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171002

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171031

R150 Certificate of patent or registration of utility model

Ref document number: 6238977

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees